Scientists have modified a medicine for high blood pressure into one that might tame misfolded protein diseases, they report in the April 10 Science. The new molecule, dubbed Sephin1, countered the effects of aggregating proteins in mouse models of amyotrophic lateral sclerosis and Charcot-Marie-Tooth disease. It might do so for other neurodegenerative disorders, speculated senior author Anne Bertolotti of the Medical Research Council Laboratory of Molecular Biology in Cambridge, England. Moreover, Sephin1 did this by selectively inhibiting dephosphorylation of a translation factor, something thought to be almost impossible because phosphatases have so many substrates.
Protein phosphatase 1C (PP1c) dephosphorylates the eukaryotic translation initiation factor 2α subunit (eIF2α), among a plethora of other protein targets. As part of the unfolded protein response (UPR) in the endoplasmic reticulum, phosphorylated eIF2α temporarily shuts down translation, giving chaperones a chance to catch up on protein folding. The UPR often kicks in to counteract accumulation of misfolded proteins in neurodegenerative disease. Dephosphorylation of eIF2α turns off the UPR and allows normal translation to resume. PP1c removes the regulatory phosphate in conjunction with one of two accessory subunits that go by the complex monikers protein phosphatase 1, regulatory subunits 15A and 15B (PPP1R15A and PPP1R15B, or R15A and R15B for short). R15B is always around, but the cell only makes R15A during times of ER stress. By promoting eIF2α dephosphorylation, these subunits ensure the cell does not go too long without making proteins, which would be lethal.
In 2011, Bertolotti reported that the anti-hypertensive drug guanabenz binds to R15A, but not R15B, and inhibits eIF2α dephosphorylation. Guanabenz protected cells from misfolded proteins and tunicamycin, a drug that induces ER stress (Tsaytler et al., 2011). Other scientists have reported that guanabenz treatment slows down disease in mouse models of ALS (Wang et al., 2014; Jiang et al., 2014), multiple sclerosis (Way et al., 2015), and prion disease (Tribouillard-Tanvier et al., 2008).
Unfortunately, guanabenz has side effects such as drowsiness and lethargy, and even coma after overdose (Hall et al., 1985). This is due to activation of the α2-adrenergic receptor, causing a potent reduction in blood pressure. Guanabenz was designed and approved as an anti-hypertensive in 1982, but it fell out of use when better medications came along. Bertolotti and first author Indarjit Das sought to eliminate α2 binding, while preserving activity in the UPR.
From a panel of guanabenz derivatives, the authors zeroed in on one missing a chlorine (see image above). They christened it Sephin1, for “selective inhibitor of a holophosphatase.” Like guanabenz, Sephin1 only bound and inhibited R15A, not R15B. Sephin1 treatment rescued cells exposed to tunicamycin, but not cells missing R15A, confirming it worked via that subunit.
Maintaining this specificity for R15A was crucial, Bertolotti said. By subduing R15A, Sephin1 prolongs the phosphorylation of eIF2α in times of stress, but eventually R15B kicks in and dephosphorylates eIF2α, allowing translation to resume. In addition, Sephin1 did not interact with the α2-adrenergic receptor.
Those cell-culture experiments indicated that Sephin1 might avoid the undesirable side effects of guanabenz, which Das next tested by treating healthy 1-month-old mice with oral Sephin1, twice a day for a month. While guanabenz-treated mice toppled off a rotating rod due to lethargy, Sephin1-treated mice had no balance problems. The treated young mice gained weight as fast as untreated controls. Since eIF-2α plays a role in memory (see Apr 2015 news), Das also tested the mice for their ability to find a hidden platform in a water maze, and to associate a sound with a foot shock in fear-cue experiments. Treated mice had no problems with either. Bertolotti said the researchers have continued the Sephin1 treatment for as long as six months. “For those six months, we see no side effects whatsoever,” she said.
What about treating disorders of protein misfolding? The researchers tested Sephin1 in a mutant SOD1 mouse model of fast-progressing ALS. They selected this model, Bertolotti said, because there was already evidence from genetic studies that knocking down R15A protected a slower-progressing version of mSOD1 mice (Wang et al., 2014). Das treated the animals with daily Sephin1 or control vehicle solution for seven weeks, beginning at when they were four weeks old. The Sephin1 mice grew faster and balanced better on the rotating rod. “The SOD1 mice treated with Sephin1 behave almost like normal,” Bertolotti wrote in an email to Alzforum.
When examined a month later, the Sephin1-treated mice contained more motor neurons in the lumbar spinal cord than the untreated mSOD1 controls, again almost matching wild-type controls. The Sephin1 treatment greatly reduced the amount of insoluble, presumably misfolded, SOD1 in spinal cord extracts, though they had normal amounts of SOD1 protein overall. The Sephin1 mice also expressed fewer markers of ER stress. “It looks like we have improved [SOD1] folding ,” Bertolotti said.
Raymond Roos of the University of Chicago, who was not involved in the work, said he would have liked to see how Sephin1 affected survival. Given the effects on weight, motor neuron number, and SOD1 solubility, he said, “I would be surprised if there was not a significant survival effect.” Bertolotti told Alzforum that those studies, which require more animals, are now in the works.
Sephin1 also helps mice that mimic a form of Charcot-Marie-Tooth neuropathy. Might it have broader effects against misfolding of neurodegeneration-related proteins, such as Aβ or tau? “Since they show this striking protective effect, it is worth trying in other neurodegenerative diseases,” commented Yang Hu of Temple University School of Medicine in Philadelphia, who did not participate in the study. However, he cautioned that Sephin1 is far from a shoo-in. Researchers have not confirmed that ER stress due to protein aggregates is a generalized cause of neurodegeneration, he pointed out. Bertolotti suspects that Sephin1 or a similar molecule would benefit more diseases than just ALS and CMT, but probably not all neurodegenerative conditions.
Hu and Roos were not entirely convinced that prolonging eIF2α phosphorylation was the only mechanism at work, either. Roos pointed out that R15A also dampens inflammation (Mesman et al., 2014). Bertolotti said R15A probably affects inflammation because of its influence on eIF2α. She is convinced that Sephin1 has no other mechanism of action because it mimics R15A knockout.
Jeroen Hoozemans and Wiep Scheper of VU University Medical Center in Amsterdam added that some studies suggest that eIF2α phosphorylation would be detrimental, not beneficial. Inhibition of PERK, the kinase that phosphorylates and activates eIF2α, protected mice from prion disease (see Oct 2013 news). “The control of eIF2α phosphorylation and dephosphorylation is very complex,” they wrote in an email to Alzforum. “For translation to human neurodegeneration, better understanding of how eIF2α is affected and controlled in different neurodegenerative diseases is required.”—Amber Dance
- Memory Maker or Neuron Killer? For Transcription Factor, It May Depend on Mood
- PERKing Up Protein Synthesis May Prevent Neurodegeneration
- Tsaytler P, Harding HP, Ron D, Bertolotti A. Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis. Science. 2011 Apr 1;332(6025):91-4. Epub 2011 Mar 3 PubMed.
- Wang L, Popko B, Tixier E, Roos RP. Guanabenz, which enhances the unfolded protein response, ameliorates mutant SOD1-induced amyotrophic lateral sclerosis. Neurobiol Dis. 2014 Nov;71:317-24. Epub 2014 Aug 15 PubMed.
- Jiang HQ, Ren M, Jiang HZ, Wang J, Zhang J, Yin X, Wang SY, Qi Y, Wang XD, Feng HL. Guanabenz delays the onset of disease symptoms, extends lifespan, improves motor performance and attenuates motor neuron loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. Neuroscience. 2014 Sep 26;277:132-8. Epub 2014 Mar 31 PubMed.
- Way SW, Podojil JR, Clayton BL, Zaremba A, Collins TL, Kunjamma RB, Robinson AP, Brugarolas P, Miller RH, Miller SD, Popko B. Pharmaceutical integrated stress response enhancement protects oligodendrocytes and provides a potential multiple sclerosis therapeutic. Nat Commun. 2015 Mar 13;6:6532. PubMed.
- Tribouillard-Tanvier D, Béringue V, Desban N, Gug F, Bach S, Voisset C, Galons H, Laude H, Vilette D, Blondel M. Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions. PLoS One. 2008;3(4):e1981. PubMed.
- Hall AH, Smolinske SC, Kulig KW, Rumack BH. Guanabenz overdose. Ann Intern Med. 1985 Jun;102(6):787-8. PubMed.
- Wang L, Popko B, Roos RP. An enhanced integrated stress response ameliorates mutant SOD1-induced ALS. Hum Mol Genet. 2014 May 15;23(10):2629-38. Epub 2013 Dec 23 PubMed.
- Mesman AW, Zijlstra-Willems EM, Kaptein TM, de Swart RL, Davis ME, Ludlow M, Duprex WP, Gack MU, Gringhuis SI, Geijtenbeek TB. Measles virus suppresses RIG-I-like receptor activation in dendritic cells via DC-SIGN-mediated inhibition of PP1 phosphatases. Cell Host Microbe. 2014 Jul 9;16(1):31-42. PubMed.
- Nishitoh H, Kadowaki H, Nagai A, Maruyama T, Yokota T, Fukutomi H, Noguchi T, Matsuzawa A, Takeda K, Ichijo H. ALS-linked mutant SOD1 induces ER stress- and ASK1-dependent motor neuron death by targeting Derlin-1. Genes Dev. 2008 Jun 1;22(11):1451-64. PubMed.
- Tribouillard-Tanvier D, Dos Reis S, Gug F, Voisset C, Béringue V, Sabate R, Kikovska E, Talarek N, Bach S, Huang C, Desban N, Saupe SJ, Supattapone S, Thuret JY, Chédin S, Vilette D, Galons H, Sanyal S, Blondel M. Protein folding activity of ribosomal RNA is a selective target of two unrelated antiprion drugs. PLoS One. 2008 May 14;3(5):e2174. PubMed.
- Moreno JA, Radford H, Peretti D, Steinert JR, Verity N, Martin MG, Halliday M, Morgan J, Dinsdale D, Ortori CA, Barrett DA, Tsaytler P, Bertolotti A, Willis AE, Bushell M, Mallucci GR. Sustained translational repression by eIF2α-P mediates prion neurodegeneration. Nature. 2012 May 24;485(7399):507-11. PubMed.
- Das I, Krzyzosiak A, Schneider K, Wrabetz L, D'Antonio M, Barry N, Sigurdardottir A, Bertolotti A. Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit. Science. 2015 Apr 10;348(6231):239-42. PubMed.